Health Canada approves Lundbeck's (Pr)VYEPTI? (eptinezumab)--the first and only intravenous preventive treatment for migraine

VYEPTI??is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was purposefully developed for IV administration. The efficacy and safety of VYEPTI??was demonstrated in two phase III clinical trials (PROMISE-1 in episodic migraine
Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches, typically accompanied by an array of symptoms including nausea, vomiting, and sensitivity to light or sound. It is estimated to affect 2-3 million Canadians and more than 1.3 billion worldwide, and impacts three times as many women than men.4 Migraine is the second leading cause of years lived with disability (YLD) among all diseases and is the top YLD cause among patients aged 15 to 49 years, according to the Global Burden of Disease study.5??Migraine has a profound impact on people's lives, their relationships, as well as their ability to carry out activities of daily living. It has been estimated that migraine accounts for 7 million lost working days annually in?Canada.4 Lundbeck contact
Lundbeck is dedicated to keeping physicians informed about the status and availability of VYEPTI??in?Canada. In addition to requested communications including emails from head office and representatives, physicians can also contact Lundbeck Canada General Inquiries at 1-800-586-2325 Ext. 5. About Lundbeck
Lundbeck is a global biopharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs, and our products are available in more than 100 countries. We have research centres in?Denmark?and the US, and our production facilities are located in?Denmark,?France, and?Italy. Lundbeck generated revenue of?DKK 17 billion?in 2019 (CAD 3.5 billion).